|1.||Shannon, H E: 2 articles (09/2001 - 09/2000)|
|2.||Li, D L: 1 article (09/2001)|
|3.||Simmons, R M: 1 article (09/2001)|
|4.||Jones, C K: 1 article (09/2001)|
|5.||Iyengar, S: 1 article (09/2001)|
|6.||Peters, S C: 1 article (09/2001)|
|7.||Womer, D E: 1 article (09/2000)|
11/03/1995 - "A method for determining a selective muscarinic agent, LY297802 (compound I), [(3-(3-1-butylthio)-1,2,5-thiadiazol-4-yl)-1-azabicyclo-2.2.2-octa ne], indicated in the treatment of pain, in rat, rabbit, and monkey plasma is described. "
09/01/2000 - "Moreover, the present results suggest that muscarinic receptor agonists such as vedaclidine may be useful in the treatment of persistent pain states that are due at least in part to dysfunction of inhibitory second messenger systems."
09/01/2001 - "The present studies demonstrate that vedaclidine produces antihyperalgesic effects in models involving central sensitization, suggesting that vedaclidine, and potentially other muscarinic receptor agonists, may have clinical utility in the management of pain states involving central sensitization, such as neuropathic and inflammatory pain states."
09/01/2001 - "Vedaclidine (0.3-10 mg/kg s.c.) produced dose-related antihyperalgesic effects in the formalin test as well as a dose-related reversal of capsaicin-induced mechanical hyperalgesia in rats. "
09/01/2001 - "In the carrageenan test, vedaclidine (0.1-30 mg/kg) produced a dose-related reversal of both mechanical and thermal hyperalgesia that were antagonized by the muscarinic receptor antagonist scopolamine. "
09/01/2000 - "Oxotremorine, H-TZTP and methylthio[2.2.1] produced dose-related reversals of PTX-induced thermal allodynia whereas vedaclidine produced a partial reversal and RS86 and pilocarpine, as well as physostigmine and tacrine, failed to reverse the allodynia. "
|1.||Muscarinic Receptors (Muscarinic Acetylcholine Receptor)